Corcept Therapeutics faces challenges despite positive analyst outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2024
0mins
Should l Buy CORT?
Source: TipRanks
Corcept Therapeutics Inc (CORT) experienced a significant decline of 8.96%, crossing below its 5-day SMA. This movement occurs amid broader market weakness, with the Nasdaq-100 down 0.48% and the S&P 500 down 0.77%.
Despite the stock's drop, analysts maintain a positive outlook for Corcept, particularly highlighting the potential of its Korlym medication. H.C. Wainwright has reiterated a Buy rating with a price target of $145, citing strong growth prospects and anticipated sales from the upcoming relacorilant launch for Cushing’s syndrome, projected to reach $4.3 billion by 2034. However, Wolfe Research has noted potential near-term hurdles due to patent litigation and antitrust cases, which could impact the stock's performance.
The implications of these developments suggest that while Corcept has promising products in the pipeline, the current market conditions and legal challenges may weigh on investor sentiment, leading to the recent price decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 33.990
Low
50.00
Averages
91.00
High
121.00
Current: 33.990
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, highlighting investor concerns over potential losses.
- Disclosure Failures: Corcept and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which severely undermined investor confidence in the company's new drug application.
- Stock Price Plunge: Following the December 31, 2025 disclosure of the FDA's Complete Response Letter regarding its new drug application, Corcept's stock price plummeted by 50.4%, from $70.20 to $34.80, indicating a pessimistic outlook from the market on the company's future prospects.
- Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, reflecting a strong demand among investors for recovering economic losses.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the clinical trials supporting the NDA for relacorilant, claiming that the evidence was “powerful support,” while the FDA had raised concerns about its adequacy, resulting in significant investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Navan and Corcept Face Class Action Lawsuits
- Navan IPO Issues: Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25 each, but due to undisclosed increases in sales and marketing expenses, its stock plummeted to $9.01 by the time the lawsuit commenced, representing a decline of over 60%, resulting in significant investor losses.
- Lawsuit Deadlines: Navan shareholders must petition to serve as lead plaintiff by April 24, 2026, reflecting investor concerns over the company's transparency and financial health, which could impact future fundraising capabilities.
- Corcept Approval Risks: Corcept's relacorilant faced a Complete Response Letter from the FDA on December 31, 2025, requiring additional evidence of effectiveness, causing its stock price to drop from $70.20 to $34.80, a 50.4% decline, highlighting significant uncertainties in the company's drug development.
- FDA Communication Missteps: During the class period, Corcept claimed smooth communication with the FDA and confidence in its NDA submission, but the FDA's concerns about clinical evidence raised the risk of non-approval, exacerbating investor confidence issues.
See More
Shareholder Class Action Filed Against Corcept Therapeutics
- Lawsuit Background: A shareholder class action lawsuit has been filed against Corcept Therapeutics, alleging that the company issued false and misleading statements regarding clinical trials and failed to disclose adverse facts related to its New Drug Application, potentially leading to investor losses.
- Investor Impact: Investors who purchased Corcept shares between October 31, 2024, and December 30, 2025, and experienced significant losses are encouraged to consult legal counsel to understand their rights, which could affect the company's stock price and investor confidence.
- Legal Representation: Holzer & Holzer, LLC, a law firm focused on shareholder rights and rated top by ISS from 2021 to 2025, is dedicated to vigorously representing shareholders, which may impact the company's reputation and future legal standing.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by April 21, 2026, or risk losing the opportunity to participate in the lawsuit, which could further affect the company's legal liabilities and financial health.
See More
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging misleading statements made to investors between October 31, 2024, and December 30, 2025, resulting in significant investor losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept misrepresented the regulatory viability of its lead product, relacorilant, despite multiple warnings from the FDA regarding inadequate clinical data, which misled investors about the drug's approval prospects.
- Stock Price Plunge: On December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80 following the receipt of a Complete Response Letter from the FDA, erasing over $3.6 billion in market value, indicating a severe market reaction to the company's disclosures.
- Investor Rights Protection: Hagens Berman urges investors who purchased CORT stock during the class period to contact the firm by April 21, 2026, to discuss their rights and potential recovery of losses, emphasizing the importance of protecting investor interests in light of the allegations.
See More
Kyndryl and Others Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. (NYSE:KD) faces a class action lawsuit for materially misstated financial statements during the period from August 7, 2024, to February 9, 2026, with a lead plaintiff deadline of April 13, 2026, potentially impacting the company's reputation and stock volatility.
- PayPal Legal Issues: PayPal Holdings, Inc. (NASDAQ:PYPL) is accused in a class action lawsuit from February 25, 2025, to February 2, 2026, of failing to effectively execute its branded checkout initiatives, with a lead plaintiff deadline of April 20, 2026, which could affect its market competitiveness and investor confidence.
- NuScale Risk Disclosure: NuScale Power Corporation (NYSE:SMR) faces legal challenges in a class action lawsuit from May 13, 2025, to November 6, 2025, for not disclosing risks associated with its partnership with ENTRA1, with a lead plaintiff deadline of April 20, 2026, potentially hindering its commercialization strategy.
- Corcept Regulatory Challenges: Corcept Therapeutics Incorporated (NASDAQ:CORT) is involved in a class action lawsuit from October 31, 2024, to January 30, 2026, due to FDA concerns regarding the adequacy of its drug effectiveness assessment, with a lead plaintiff deadline of April 21, 2026, which may impact its drug approval process and company outlook.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, highlighting investor concerns over potential losses.
- Disclosure Failures: Corcept and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which severely undermined investor confidence in the company's new drug application.
- Stock Price Plunge: Following the December 31, 2025 disclosure of the FDA's Complete Response Letter regarding its new drug application, Corcept's stock price plummeted by 50.4%, from $70.20 to $34.80, indicating a pessimistic outlook from the market on the company's future prospects.
- Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, reflecting a strong demand among investors for recovering economic losses.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the clinical trials supporting the NDA for relacorilant, claiming that the evidence was “powerful support,” while the FDA had raised concerns about its adequacy, resulting in significant investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Navan and Corcept Face Class Action Lawsuits
- Navan IPO Issues: Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25 each, but due to undisclosed increases in sales and marketing expenses, its stock plummeted to $9.01 by the time the lawsuit commenced, representing a decline of over 60%, resulting in significant investor losses.
- Lawsuit Deadlines: Navan shareholders must petition to serve as lead plaintiff by April 24, 2026, reflecting investor concerns over the company's transparency and financial health, which could impact future fundraising capabilities.
- Corcept Approval Risks: Corcept's relacorilant faced a Complete Response Letter from the FDA on December 31, 2025, requiring additional evidence of effectiveness, causing its stock price to drop from $70.20 to $34.80, a 50.4% decline, highlighting significant uncertainties in the company's drug development.
- FDA Communication Missteps: During the class period, Corcept claimed smooth communication with the FDA and confidence in its NDA submission, but the FDA's concerns about clinical evidence raised the risk of non-approval, exacerbating investor confidence issues.
See More
Shareholder Class Action Filed Against Corcept Therapeutics
- Lawsuit Background: A shareholder class action lawsuit has been filed against Corcept Therapeutics, alleging that the company issued false and misleading statements regarding clinical trials and failed to disclose adverse facts related to its New Drug Application, potentially leading to investor losses.
- Investor Impact: Investors who purchased Corcept shares between October 31, 2024, and December 30, 2025, and experienced significant losses are encouraged to consult legal counsel to understand their rights, which could affect the company's stock price and investor confidence.
- Legal Representation: Holzer & Holzer, LLC, a law firm focused on shareholder rights and rated top by ISS from 2021 to 2025, is dedicated to vigorously representing shareholders, which may impact the company's reputation and future legal standing.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by April 21, 2026, or risk losing the opportunity to participate in the lawsuit, which could further affect the company's legal liabilities and financial health.
See More
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging misleading statements made to investors between October 31, 2024, and December 30, 2025, resulting in significant investor losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept misrepresented the regulatory viability of its lead product, relacorilant, despite multiple warnings from the FDA regarding inadequate clinical data, which misled investors about the drug's approval prospects.
- Stock Price Plunge: On December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80 following the receipt of a Complete Response Letter from the FDA, erasing over $3.6 billion in market value, indicating a severe market reaction to the company's disclosures.
- Investor Rights Protection: Hagens Berman urges investors who purchased CORT stock during the class period to contact the firm by April 21, 2026, to discuss their rights and potential recovery of losses, emphasizing the importance of protecting investor interests in light of the allegations.
See More
Kyndryl and Others Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. (NYSE:KD) faces a class action lawsuit for materially misstated financial statements during the period from August 7, 2024, to February 9, 2026, with a lead plaintiff deadline of April 13, 2026, potentially impacting the company's reputation and stock volatility.
- PayPal Legal Issues: PayPal Holdings, Inc. (NASDAQ:PYPL) is accused in a class action lawsuit from February 25, 2025, to February 2, 2026, of failing to effectively execute its branded checkout initiatives, with a lead plaintiff deadline of April 20, 2026, which could affect its market competitiveness and investor confidence.
- NuScale Risk Disclosure: NuScale Power Corporation (NYSE:SMR) faces legal challenges in a class action lawsuit from May 13, 2025, to November 6, 2025, for not disclosing risks associated with its partnership with ENTRA1, with a lead plaintiff deadline of April 20, 2026, potentially hindering its commercialization strategy.
- Corcept Regulatory Challenges: Corcept Therapeutics Incorporated (NASDAQ:CORT) is involved in a class action lawsuit from October 31, 2024, to January 30, 2026, due to FDA concerns regarding the adequacy of its drug effectiveness assessment, with a lead plaintiff deadline of April 21, 2026, which may impact its drug approval process and company outlook.
See More
